esc
Search documents
go
Browse entities
go
Corpus stats
go
About the data
go
AI settings
go
EFTA
Search
Search
Entities
About
Stats
Settings
⌘K
search
Search
Search syntax help
Dataset
Set 1
Set 2
Set 3
Set 4
Set 5
Set 6
Set 7
Set 8
Set 9
Set 10
Set 11
Set 12
Sort
Relevance
Most pages
Most words
Dataset
Newest
Oldest
Status
All
Extracted
Failed
DOJ Status
All
Removed
Available
Modified
Date Range
Undated only
–
Email Headers
Page Count
–
Saved Searches
+
15 results for “
"Enterococci"
”
Export
Keyboard Shortcuts
/
Focus search
Esc
Blur input
O
Open PDF
←
→
Paginate
EFTA00902109
Dataset 9
2011-01-21
3p
622w
Subject:
Re: IMDx Enters into Agreement with Abbott
From:
Jeffrey Epstein <
[email protected]
>
To:
Alice Jacobs
…worldwide. Financial terms have not been disclosed. IMDx tests are state of the art incorporating important and evolving clinical needs. The tests are designed utilizing IMDx's proprietary bioinformatics process which ensures high performing products that are optimized and in silico verified. Tests will include identification of the following infectious organisms, Clostridium difficile, Vancomycin- Resistance
Enterococci
(VRE), Group B Streptococci (GBS), Influenza A/Influenza B (INFA/B), and Herpes Simplex Virus 1 and 2 (HSV 1/2). In addition, two…
https://www.justice.gov/epstein/files/DataSet%209/EFTA00902109.pdf
EFTA00920661
Dataset 9
2011-09-28
2p
619w
Subject:
IMDx Introduces CE-marked Assay for VanR for European Market and ROW
From:
"Alice Jacobs" •
To:
"Denise Marston"
…Test for the Detection of Vancomycin Resistance Genes vanA and vanB Most Commonly Found in Vancomycin-Resistant
Enterococci
Cambridge, MA, September 21, 2011- IntelligentMDx (IMDx) announced today that it has received CE-Mark for its second automated molecular test for the Abbott FDA cleared m2000 instrument. The IMDx"' VanR for Abbott m2000" test accurately detects and distinguishes the vanA and vanB genes most commonly found in vancomycin-resistant
enterococci
(VRE) in specimens from patients at risk for colonization or infection…
https://www.justice.gov/epstein/files/DataSet%209/EFTA00920661.pdf
EFTA00920674
Dataset 9
2011-09-28
2p
672w
Subject:
Fwd: IMDx Introduces CE-marked Assay for VanR for European Market and ROW
From:
jeffrey epstein <
[email protected]
>
To:
Boris Nikolic
…for the Detection of Vancomycin Resistance Genes vanA and vanB Most Commonly Found in Vancomycin-Resistant
Enterococci
Cambridge, MA, September 21, 2011 — IntelligentMDx (IMDx) announced today that it has received CE-Mark for its second automated molecular test for the Abbott FDA cleared m2000 instrument. The IMDxTM VanR for Abbott m2000TM test accurately detects and distinguishes the vanA and vanB genes most commonly found in vancomycin-resistant
enterococci
(VRE) in specimens from patients at risk for colonization or infection. Detection…
https://www.justice.gov/epstein/files/DataSet%209/EFTA00920674.pdf
EFTA00614609
Dataset 9
2011-01-20
1p
379w
…worldwide. Financial terms have not been disclosed. IMDx tests are state of the art incorporating important and evolving clinical needs. The tests are designed utilizing IMDx's proprietary bioinformatics process which ensures high performing products that are optimized and in silico verified. Tests will include identification of the following infectious organisms. Clostridium difficile, Vancomycin-Resistance
Enterococci
(VRE), Group B Streptococci (GBS), Influenza A/Influenza B (INFA/B), and Herpes Simplex Virus 1 and 2 (HSV 1/2). In addition, two…
https://www.justice.gov/epstein/files/DataSet%209/EFTA00614609.pdf
EFTA00703494
Dataset 9
2013-07-30
2p
647w
Subject:
MDx Receives FDA Clearance for IMDx VanR for Abbott m2000 assay
From:
Alice Jacobs <I
To:
Denise Marston <I
…I hope you are doing well and are having a great summer. I am pleased to announce that IMDx has achieved a pivotal milestone with the receipt of FDA clearance for its Vancomycin Resistance (VanR) test for the Abbott m2000 system. This test detects vancomycin-resistance genes that can be associated with vancomycin resistant
enterococci
(VRE.) VRE are bacteria which have become resistant to the antibiotic vancomycin, and are responsible for a variety of healthcare- associated infections, including surgical wound…
https://www.justice.gov/epstein/files/DataSet%209/EFTA00703494.pdf
EFTA00671769
Dataset 9
2012-07-30
1p
210w
Subject:
IMDx Obtains CE-marking for HSV Assay
From:
"Alice Jacobs" <I
To:
"Denise Marston" <
…and neonatal sepsis. We are proud to add HSV 1/2 to our expanding infectious disease testing portfolio, which includes tests for hospital-acquired infections including C. difficile and vancomycin-resistant
enterococci
and prenatal screening of Group B Streptococcus. My best, Alice Alice A. Jacobs, M.D. Chairman 8 CEO IntelligentMDx 19 Blackstone Street Cambridee. MA 02139 Phone: Cell: Fax Email: Visit us at www.intelligentMDx.com The information transmitted is intended only for the person or entity to which…
https://www.justice.gov/epstein/files/DataSet%209/EFTA00671769.pdf
EFTA00934705
Dataset 9
2012-05-15
2p
629w
Subject:
IMDx Obtains CE-marking for GBS Assay for screening for neonatal infections
From:
"Alice Jacobs"
To:
"Denise Marston" ctl
…including sepsis, meningitis, and pneumonia. We are proud to add GBS to our expanding infectious disease testing portfolio, which includes tests hospital-acquired infections including C. difficile and vancomycin-resistant
enterococci
. My best, Alice IntelligentMDx Announces CE-Marking of a new high-throughput test for Group B Streptococcus intended to improve women's health and prenatal care Cambridge, MA, May 15, 2012 — IntelligentMDx (IMDx) announced today that it has obtained CE-marking for a new automated, high-throughput, qualitative in…
https://www.justice.gov/epstein/files/DataSet%209/EFTA00934705.pdf
EFTA00718974
Dataset 9
2012-03-13
2p
705w
Subject:
RE: Dr. Alice Jacobs, CEO of IntelligentMDx, Honored as a 2012 Mass High Tech Woman to
From:
Boris Nikolic
To:
Jeffrey Epstein <
[email protected]
>
…diseases. In 2011, IMDx released two CE-marked diagnostic kits, which are being distributed globally by Abbott, targeting two of the most threatening healthcare-associated infections, Clostridium dinette, and vancomycin-resistant
enterococci
. Diagnostic tests for Group B streptococcus and Influenza MB and RSV are scheduled to obtain CE-marking and launch in the spring of 2012. The IMDx pipeline also includes additional assays targeting oncology, human genetics and companion diagnostics. IMDx employs experts from diverse backgrounds including financial, legal, scientific…
https://www.justice.gov/epstein/files/DataSet%209/EFTA00718974.pdf
EFTA00605649
Dataset 9
2p
445w
…QlAsymphony RGQ MDx System, was CE-marked in March 2014. The artus VanR QS-RGQ Kit is intended as an aid to identify, prevent, and control vancomycin-resistant colonization in patients at risk for vancomycin-resistant
enterococci
infection. A Premarket Notification 510(k) submission for the test is being submitted shortly to FDA for review. "The global burden of HAls is significant, with approximately 1 in 14 hospitalized patients acquiring an infection during their stay," says Dr. Alice Nesselrodt, Chairman &…
https://www.justice.gov/epstein/files/DataSet%209/EFTA00605649.pdf
EFTA00640072
Dataset 9
2011-01-20
2p
505w
Subject:
IMDx Enters into Agreement with Abbott
From:
"Alice Jacobs"
To:
"Alice Jacobs"
…worldwide. Financial terms have not been disclosed. IMDx tests are state of the art incorporating important and evolving clinical needs. The tests are designed utilizing IMDx's proprietary bioinformatics process which ensures high performing products that are optimized and in silica verified. Tests will include identification of the following infectious organisms, Clostridium difficile, Vancomycin-Resistance
Enterococci
(VRE), Group B Streptococci (GBS), Influenza A/Influenza B (INFA/B), and Herpes Simplex Virus 1 and 2 (HSV 1/2). In addition, two…
https://www.justice.gov/epstein/files/DataSet%209/EFTA00640072.pdf
EFTA00662732
Dataset 9
2014-05-08
2p
680w
Subject:
IMDx achieves 4th FDA clearance--QIAGEN anus C difficile QS-RGQ MDx--a test for a
From:
Alice Jacobs Nesselrodt
To:
Alice Jacobs Nesselrodt
…QIAGEN QlAsymphony RGQ MDx System, was CE-marked in March 2014. The artus VanR QS-RGQ Kit is intended as an aid to identify, prevent, and control vancomycin-resistant colonization in patients at risk for vancomycin-resistant
enterococci
infection. A Premarket Notification S10(k) submission for the test is being submitted shortly to FDA for review. "The global burden of HAIs is significant, with approximately 1 in 14 hospitalized patients acquiring an infection during their stay," says Dr. Alice Nesselrodt…
https://www.justice.gov/epstein/files/DataSet%209/EFTA00662732.pdf
EFTA00924754
Dataset 9
2011-11-30
3p
932w
Subject:
Fwd: Dr. Alice Jacobs, CEO of IntelligentMDx, Named Best Entrepreneur in Eighth Annual
From:
Jeffrey Epstein <jeevacationggmail.com>
To:
Boris Nikolie
…recognized as a Stevie Award Winner." To date, IMDx has released two CE-marked diagnostic kits, which are being distributed globally by Abbott, targeting two of the most threatening healthcare-associated infections, Clostridium difficile, and vancomycin-resistant
enterococci
. The IMDx pipeline includes a range of infectious disease assays, a subset of which are currently being distributed globally by Abbott, as well as additional assays targeting oncology, human genetics and companion diagnostics. IMDx's platform-agnostic approach and bioinformatics-driven assay…
https://www.justice.gov/epstein/files/DataSet%209/EFTA00924754.pdf
EFTA00648481
Dataset 9
2011-01-21
2p
669w
Subject:
RE: IMDx Enters into Agreement with Abbott
From:
"Alice Jacobs" •
To:
"Jeffrey Epstein" <
[email protected]
>
…worldwide. Financial terms have not been disclosed. IMDx tests are state of the art incorporating important and evolving clinical needs. The tests are designed utilizing IMDx's proprietary bioinformatics process which ensures high performing products that are optimized and in silica verified. Tests will include identification of the following infectious organisms, Clostridium difficile, Vancomycin-Resistance
Enterococci
(VRE), Group B Streptococci (GBS), Influenza A/Influenza B (INFA/B), and Herpes Simplex Virus 1 and 2 (HSV 1/2). In addition, two…
https://www.justice.gov/epstein/files/DataSet%209/EFTA00648481.pdf
EFTA00719780
Dataset 9
2011-11-29
2p
812w
Subject:
Dr. Alice Jacobs, CEO of IntelligentMDx, Named Best Entrepreneur in Eighth Annual StevieR
From:
"Alice Jacobs"
To:
"Renda Hawwa" .<• >
…recognized as a Stevie Award Winner." To date, IMDx has released two CE-marked diagnostic kits, which are being distributed globally by Abbott, targeting two of the most threatening healthcare-associated infections, Clostridium difficile, and vancomycin-resistant
enterococci
. The IMDx pipeline includes a range of infectious disease assays, a subset of which are currently being distributed globally by Abbott, as well as additional assays targeting oncology, human genetics and companion diagnostics. IMDx's platform-agnostic approach and bioinformatics-driven assay…
https://www.justice.gov/epstein/files/DataSet%209/EFTA00719780.pdf
EFTA00930939
Dataset 9
2012-03-13
3p
654w
Subject:
Fwd: Dr. Alice Jacobs, CEO of IntelligentMDx, Honored as a 2012 Mass High Tech Woman to
From:
Jeffrey Epstein <
[email protected]
>
To:
Boris Nikolic
…diseases. In 2011, IMDx released two CE-marked diagnostic kits, which are being distributed globally by Abbott, targeting two of the most threatening healthcare-associated infections, Clostridium dinette, and vancomycin-resistant
enterococci
. Diagnostic tests for Group B streptococcus and Influenza MB and RSV are scheduled to obtain CE-marking and launch in the spring of 2012. The IMDx pipeline also includes additional assays targeting oncology, human genetics and companion diagnostics. IMDx employs experts from diverse backgrounds including financial, legal, scientific…
https://www.justice.gov/epstein/files/DataSet%209/EFTA00930939.pdf
Corpus: 1990-03-17 – 2025-12-01
←
January 2011
→
Mo
Tu
We
Th
Fr
Sa
Su
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
Undated
(150,429)
None
Light
Medium
Heavy
Results by Dataset
15 total
Set 9
15